Neurosteroid allopregnanolone attenuates development of nicotine withdrawal behavior in mice

Neuroscience Letters

Volumn 541, Issue , 2013, Pages 144-149

  Thakre, Prajwal P ^a   Tundulwar, Meher R ^a   Chopde, Chandrabhan T ^a   Ugale, Rajesh R ^a,b  

^a New Kamptee   (India)

^b GURU GHASIDAS UNIVERSITY   (India)

Author keywords

Allopregnanolone; Nicotine withdrawal behavior; Progesterone

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; FINASTERIDE; INDOMETACIN; NICOTINE; PROGESTERONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; LOCOMOTION; MALE; MOUSE; NICOTINE WITHDRAWAL; NONHUMAN; PRIORITY JOURNAL; TOBACCO DEPENDENCE; TRANQUILIZING ACTIVITY; WITHDRAWAL SYNDROME;

ANIMALS; ANXIETY; FINASTERIDE; INDOMETHACIN; MALE; MAZE LEARNING; MICE; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; NICOTINE; PREGNANOLONE; PROGESTERONE; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 84876410241     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.02.023     Document Type: Article

References (26)

1. Allen S.S., Allen A.M., Lunos S., Hatsukami D.K. Patterns of self-selected smoking cessation attempts and relapse by menstrual phase. Addict. Behav. 2009, 34:928-931.
2. Beyer C., González-Flores O., Ramírez-Orduña J.M., González-Mariscal G. Indomethacin inhibits lordosis induced by ring A-reduced progestins: possible role of 3alpha-oxoreduction in progestin-facilitated lordosis. Horm. Behav. 1999, 35:1-8.
3. Bixo M., Andersson A., Winblad B., Purdy R.H., Backstrom T. Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 1997, 764:173-178.
4. Compagnone N.A., Mellon S.H. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front. Neuroendocrinol. 2000, 21:1-56.
5. Concas A., Sogliano C., Porcu P., Marra C., Brundu A., Biggio G. Neurosteroids in nicotine and morphine dependence. Psychopharmacology (Berl) 2006, 186:281-292.
6. D'Souza M.S., Markou A. Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict. Sci. Clin. Pract. 2011, 6:4-16.
7. Guidotti A., Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3-alpha, 5-alpha-tetrahydroprogesterone (allopregnanolone) availability. Biol. Psychiatry 1998, 44:865-873.
8. Hartwell K.J., Johnson K.A., Li X., Myrick H., LeMatty T., George M.S., Brady K.T. Neural correlates of craving and resisting craving for tobacco in nicotine dependent smokers. Addict. Biol. 2011, 10.1111/j.13691600.2011.00340.
9. Hirani K., Khisti R.T., Chopde C.T. Behavioral action of ethanol in Porsolt's forced swim test: modulation by 3-alpha-hydroxy-5-alpha-pregnan-20-one. Neuropharmacology 2002, 43:1339-1350.
10. Hirani K., Sharma A.N., Jain N.S., Ugale R.R., Chopde C.T. Evaluation of gabaergic neuroactive steroid 3alpha-hydroxy-5alpha-pregnane-20-one as a neurobiological substrate for the anti-anxiety effect of ethanol in rats. Psychopharmacology (Berl) 2005, 180:267-278.
11. Hughes J.R. Measurement of the effects of abstinence from tobacco: a qualitative review. Psychol. Addict. Behav. 2007, 21:27-37.
12. Isola R., Vogelsberg V., Wemlinger T.A., Neff N.H., Hadjiconstantinou M. Nicotine withdrawal in the mouse. Brain Res. 1999, 850:189-196.
13. Kaminski R.M., Gasior M., Carter R.B., Witkin J.M. Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice. Eur. J. Pharmacol. 2003, 474:217-222.
14. Kenny P.J., Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol. Biochem. Behav. 2001, 70:531-549.
15. Khisti R.T., Chopde C.T., Jain S.P. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol. Biochem. Behav. 2000, 67:137-143.
16. Lephart E.D., Ladle D.R., Jacobson N.A., Rhees R.W. Inhibition of brain 5a-reductase in pregnant rats: effects on enzymatic and behavioral activity. Brain Res. 1996, 739:356-360.
17. Lynch W.J., Sofuoglu M. Role of progesterone in nicotine addiction: evidence from initiation to relapse. Exp. Clin. Psychopharmacol. 2010, 18:451-461.
18. Markou A. Neurobiology of nicotine dependence. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2008, 363:3159-3168.
19. Marx C.E., Trost W.T., Shampine L., Behm F.M., Giordano L.A., Massing M.W., Rose J.E. Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers'. Psychopharmacology (Berl) 2006, 186:462-472.
20. Morrow L., VanDoren M.J., Fleming R., Penland S. Ethanol and neurosteroid interactions in the brain. Int. Rev. Neurobiol. 2001, 46:349-377.
21. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
22. Porcu P., Sogliano C., Cinus M., Purdy R.H., Biggio G., Concas A. Nicotine-induced changes in cerebrocortical neuroactive steroids and plasma corticosterone concentrations in the rat. Pharmacol. Biochem. Behav. 2003, 74:683-690.
23. Purdy R.H., Morrow A.L., Moore P.H., Paul S.M. Stress-induced elevations of gamma-aminobutyric acid type a receptor-active steroids in the rat brain. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:4553-4557.
24. Schneider P., Ho Y.J., Spanagel R., Pawlak C.R. A novel elevated plus-maze procedure to avoid the one-trial tolerance problem. Front. Behav. Neurosci. 2011, 5:43-47.
25. Sofuoglu M., Babb D.A., Hatsukami D.K. Progesterone treatment during the early follicular phase of the menstrual cycle: effects on smoking behavior in women. Pharmacol. Biochem. Behav. 2001, 69:299-304.
26. Sofuoglu M., Mitchell E., Mooney M. Progesterone effects on subjective and physiological responses to intravenous nicotine in male and female smokers. Hum. Psychopharmacol. 2009, 24:559-564.